|This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.|
This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.
Chemotherapy-induced nausea and vomiting (CINV) and other oral chemotherapy related adverse events are commonly feared by patients. Pharmacists provide many important services in caring for these patients. It is important for pharmacists to recognize CINV risk factors and know the antiemetic therapies available for the patients. The development of a large number of targeted therapies for cancer in the past decade has led to new mechanism-based adverse effects of new drug classes that affect virtually every organ system in the body. The role of the pharmacist is to provide patient and family education, healthcare provider education, side effect prevention and management. This activity provides an update for pharmacists on the antiemetic therapies available and techniques for managing the unique adverse events associated with oral chemotherapy.
The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:
- Identify chemotherapy induced nausea and vomiting (CINV) risk factors of patients receiving chemotherapy.
- List the antiemetic therapy agents available in the treatment of CINV.
- Recognize unique adverse effects associated with oral oncologics.
- Discuss how to assess and select appropriate management strategies with adverse effects associated with oral oncologics.
Megan May, PharmD, BCOP
Clinical Oncology Pharmacy Specialist
Baptist Health Lexington
Michael Heikkinen, PharmD; Jennifer Powers, PharmD; Marcy Snell, PharmD, CSP
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Jennifer Powers has served as a Consultant for Power-Pak CE. Michael Heikkinen, Megan May, and Marcy Snell have no relevant commercial and/or financial relationships to disclose.
Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
Release Date: 10-01-2018
Expiration Date: 10-01-2021
This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-18-372-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 0.75 contact hour(0.075 CEU) in states that recognize ACPE providers, and is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
This activity is self-funded by NASP.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
|Activity Number||Credit Amount||Accreditation Period|
|0221-9999-18-372-H01-P||0.75 Contact Hours||October 01, 2018 - October 01, 2021|